Long-Term Treatment with Citicoline Prevents Cognitive Decline and Predicts a Better Quality of Life after a First Ischemic Stroke

Abstract

Stroke, as the leading cause of physical disability and cognitive impairment, has a very significant impact on patients' quality of life (QoL). The objective of this study is to know the effect of citicoline treatment in Qol and cognitive performance in the long-term in patients with a first ischemic stroke. This is an open-label, randomized, parallel study of citicoline vs. usual treatment. All subjects were selected 6 weeks after suffering a first ischemic stroke and randomized into parallel arms. Neuropsychological evaluation was performed at 1 month, 6 months, 1 year and 2 years after stroke, and QoL was measured using the EuroQoL-5D questionnaire at 2 years. 163 patients were followed during 2 years. The mean age was 67.5 years-old, and 50.9% were women. Age and absence of citicoline treatment were independent predictors of both utility and poor quality of life. Patients with cognitive impairment had a poorer QoL at 2 years (0.55 vs. 0.66 in utility, p = 0.015). Citicoline treatment improved significantly cognitive status during follow-up (p = 0.005).In conclusion, treatment with long-term citicoline is associated with a better QoL and improves cognitive status 2 years after a first ischemic stroke.

Latin American Delphi Consensus on Vascular Cognitive Impairment: Definitions, Clinical Features, Pathophysiology, Prevention and Treatment

“…In addition, only the citicoline treated group (vs. standard measures) sustained cognitive improvement after the first year of treatment [232].…”

Poststroke cognitive impairment and dementia

“…В дальней-шем 163 пациента продолжили терапию цитиколином в дозе 1 г/сут внутрь в течение еще одного года. По оконча-нии 2-летного курса терапии, наряду с когнитивными функциями, оценивалось и изменение качества жизни после инсульта у пациентов, рандомизированных в группу лечения и не получавших терапии [3]. Было показано, что ухудшение когнитивных функций после инсульта, которое отмечалось через 2 года после начала заболевания у 28% пациентов в группе цитиколина и у 39% лиц, не получав-ших препарат, связано с ухудшением качества жизни.…”

The role of citicoline in the treatment of dyscirculatory encephalopathy and vascular cognitive impairment

“…[30] и в 2016 г. [31] J. Alvarez-Sabin и соавт. опубликовали результаты длительного наблюдения за пациентами, получающими терапию цитиколином.…”